227 related articles for article (PubMed ID: 10493963)
1. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Loprevite M; Favoni RE; de Cupis A; Pirani P; Merlo F; Grossi F; Ardizzoni A
Int J Oncol; 1999 Oct; 15(4):787-92. PubMed ID: 10493963
[TBL] [Abstract][Full Text] [Related]
2. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Tolis C; Peters GJ; Ferreira CG; Pinedo HM; Giaccone G
Eur J Cancer; 1999 May; 35(5):796-807. PubMed ID: 10505042
[TBL] [Abstract][Full Text] [Related]
4. Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
de Cupis A; Semino C; Pirani P; Loprevite M; Ardizzoni A; Favoni RE
Eur J Pharmacol; 2003 Jul; 473(2-3):83-95. PubMed ID: 12892825
[TBL] [Abstract][Full Text] [Related]
5. [Developed new agents for lung cancer].
Kato Y; Saijo N
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
[TBL] [Abstract][Full Text] [Related]
6. Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines.
Loprevite M; Favoni RE; de Cupis A; Pirani P; Pietra G; Bruno S; Grossi F; Scolaro T; Ardizzoni A
Lung Cancer; 2001 Jul; 33(1):27-39. PubMed ID: 11429193
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Zoli W; Ricotti L; Dal Susino M; Barzanti F; Frassineti GL; Folli S; Tesei A; Bacci F; Amadori D
Br J Cancer; 1999 Oct; 81(4):609-15. PubMed ID: 10574245
[TBL] [Abstract][Full Text] [Related]
8. New drugs for treating small cell lung cancer.
Ettinger DS
Lung Cancer; 1995 Jun; 12 Suppl 3():S53-61. PubMed ID: 7551957
[TBL] [Abstract][Full Text] [Related]
9. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
11. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents.
Ollikainen T; Knuuttila A; Suhonen S; Taavitsainen M; Jekunen A; Mattson K; Linnainmaa K
Anticancer Drugs; 2000 Feb; 11(2):93-9. PubMed ID: 10789591
[TBL] [Abstract][Full Text] [Related]
12. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
Voigt W; Kegel T; Weiss M; Mueller T; Simon H; Schmoll HJ
J Cancer Res Clin Oncol; 2005 Sep; 131(9):585-90. PubMed ID: 16021466
[TBL] [Abstract][Full Text] [Related]
13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
14. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin.
Lin X; Howell SB
Mol Pharmacol; 1999 Aug; 56(2):390-5. PubMed ID: 10419559
[TBL] [Abstract][Full Text] [Related]
15. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
Meert AP; Berghmans T; Branle F; Lemaître F; Mascaux C; Rubesova E; Vermylen P; Paesmans M; Sculier JP
Anticancer Res; 1999; 19(5C):4379-90. PubMed ID: 10650780
[TBL] [Abstract][Full Text] [Related]
16. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG
Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701
[TBL] [Abstract][Full Text] [Related]
18. [Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Yoshimasu T; Oura S; Hirai I; Kokawa Y; Hata K; Kawago M; Tanino H; Okamura Y; Furukawa T
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1013-6. PubMed ID: 16044964
[TBL] [Abstract][Full Text] [Related]
19. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Oguri T; Achiwa H; Bessho Y; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Lung Cancer; 2005 Sep; 49(3):345-51. PubMed ID: 15993511
[TBL] [Abstract][Full Text] [Related]
20. [Lung cancer].
Furuse K
Gan To Kagaku Ryoho; 1997 Oct; 24(13):1917-24. PubMed ID: 9350236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
